TecSalud del Tecnológico de Monterrey
Cardiol has entered into a letter of intent with TecSalud del Tecnológico de Monterrey (TecSalud) to collaborate on the research and development of proprietary nanotherapeutics for the treatment of heart failure. The primary objective of this collaboration is to develop the experimental evidence necessary to support advancing breakthrough nanomedicines for heart failure into clinical development during 2018.
TecSalud is committed to delivering outstanding patient care with four cutting-edge academic medical centers that combine innovative research, clinical services, and education. TecSalud has collaborative relationships with the Houston Methodist DeBakey Heart & Vascular Center and the University of Calgary, and has established a formal agreement with the Massachusetts Institute of Technology (MIT) to promote research and development in nanoscience and nanotechnology in Mexico.